Abstract: Background: Cancer is currently among the three leading causes of death after solid organ transplantation and its incidence is increasing. Non-melanoma skin cancer -squamous cell carcinoma and basal cell carcinoma -is the most common malignancy found in kidney transplant recipients (KTRs). The incidence of non-melanoma skin cancer in KTRs has not been extensively studied in Portugal. oBjectives: To determine the incidence of non-melanoma skin cancer in KTRs from the largest Portuguese kidney transplant unit; and to study risk factors for non-melanoma skin cancer. Methods: Retrospective analysis of clinical records of KTRs referred for the first time for a dermatology consultation between 2004 and 2013. A case-control study was performed on KTRs with and without non-melanoma skin cancer. results: We included 288 KTRs with a median age at transplantation of 47 years, a male gender predominance (66%) and a median transplant duration of 3.67 years. One fourth (n=71) of KTRs developed 131 non-melanoma skin cancers, including 69 (53%) squamous cell carcinomas and 62 (47%) basal cell carcinomas (ratio squamous cell carcinoma: basal cell carcinoma 1.11), with a mean of 1.85 neoplasms per patient. Forty percent of invasive squamous cell carcinomas involved at least two clinical or histological high-risk features. The following factors were associated with a higher risk of non-melanoma skin cancer: an older age at transplantation and at the first consultation, a longer transplant duration and the presence of actinic keratosis. KTRs treated with azathioprine were 2.85 times more likely to develop non-melanoma skin cancer (p=0.01). conclusion: Non-melanoma skin cancer was a common reason for dermatology consultation in Portuguese KTRs. It is imperative for KTRs to have access to specialized dermatology consultation for early referral and treatment of skin malignancies.
INTRODUCTION
Cancer is currently one of the three major causes of death among solid organ transplant recipients and its incidence has grown in recent decades. 1, 2 The two most common types of non-melanoma skin cancer (NMSC) -squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) -account for 95% of skin cancers and 40% of all neoplasms in solid organ transplant recipients. These skin tumors cause greater morbidity and mortality than in the general population. 3 The risk of SCC and BCC in KTRs is, respectively, 65-250 times and 10 times higher than in the general population. 3, 4 The oncogenesis of NMSC is multifactorial but immune surveillance reduction caused by immunosuppressive drugs, along with the direct carcinogenic effect of these agents, is enhanced by cumulative ultraviolet radiation exposure. 5, 6 The following factors also have an impact on the risk of NMSC: Fitzpatrick skin types I-III, an older age at transplantation, being Caucasian, geographic locations situated at lower latitudes, as well as infections by oncogenic viruses. 3, 7 Kidney transplantation occupies an intermediate position in the associated risk of NMSC, being lower than heart or lung transplantation, but higher than liver transplantation. 3, 5, 8 In 2013, Portugal was ranked 8 th in the world in terms of the numbers of kidney transplantations from deceased donors, with 38.3 transplants per 1 million inhabitants. 9 The incidence of NMSC in KTRs has been poorly evaluated in Portugal. The most recently published studies evaluated small samples of patients from kidney transplant units in the country's southern region and reported a limited number of NMSCs.
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OBJECTIVES
Our objectives were to determine the incidence and characterize the NMSCs in a series of patients from the largest Portuguese kidney transplant unit (in Coimbra); and to study the risk factors for NMSC in this population.
METHODS
We performed an observational retrospective study using (non-probability) purposive sampling -we included all KTRs Patients who underwent double transplants (e.g. heart, liver, lung) and patients with personal history of skin cancer were excluded.
The primary endpoint was the occurrence of NMSC (SCC or BCC) during the follow-up. We considered two groups for compari- 
ii) Diagnosed neoplasms
In this population of KTRs, the overall incidence of NMSC was 24.7% (n=71). 
Years after transplant
Cumulative incidence from 33% in the first year, to 42% in the second and 53% in the third year, following the first NMSC (Graph 2). With the exception of prednisolone -used in all patientsmycophenolate was the most prescribed drug and azathioprine was the least common antimetabolite. In the multivariate analysis, we verified that patients treated with mycophenolate presented a significantly lower risk of NMSC compared with those who were not treated with it (OR 0.288, p<0.001) ( Table 5) . Inversely, patients treated with azathioprine had a higher risk of NMSC (OR 2.85, p=0.01).
iv) Clinical and histological high-risk features of SCC
The vast majority of KTRs (93.1%) were initially prescribed with one of the four previously mentioned immunosuppressive regimens.
Importantly, regimen C -including azathioprine and cyclosporinewas associated with a 3.85 times higher risk of NMSC than regimen A, containing the more recent antimetabolite and calcineurin inhibitor -mycophenolate and tacrolimus. There were no statistically significant differences between other regimens (Table 6) . 
i) Time evolution of NMSC incidence
In this study, NMSC was diagnosed in about one fourth of KTRs over a decade. At the beginning of the 1990s, the incidence of malignant and premalignant skin lesions in a prospective study conducted in this same kidney transplant unit was considerably lower (13.4%).
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ii) NMSC incidence in other series
The overall incidence found was similar to that reported by García et al. in a recent Spanish series of 289 patients (25.2%), but higher than the rates detected in two other studies previously conducted in Lisbon, Portugal -11.7% (48/410 KTRs) and 16% (20/127 KTRs). 10, 11, 14 Although the threshold for dermatology consultation referral is low, the incidence observed may be underestimated.
iii) Cumulative incidence of first NMSC
Transplant duration (that correlates with the duration of immunosuppressive treatment) is a major risk factor for NMSC and it is translated in the increased cumulative incidence (CI) of the first and subsequent NMSCs over the post-trasnplant period, though at different magnitudes. 3 Regarding the first NMSC, CI increased almost linearly over that period, doubling between the 5 th and [14] [15] [16] Australia has one of the highest reported CIs, reaching 24.8% at 5 years. 16 As occurs in the general population, the CI of NMSC is higher with lower latitudes.
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iv) Cumulative incidence of subsequent NMSC The occurrence of the first NMSC predicts the early development of subsequent neoplasms. 17, 18 In this series, the increase in the CI of subsequent NMSCs was more pronounced within the first 3 years following the initial NMSC, reaching 53%. In a study from the Netherlands, the CI of subsequent NMSCs at the first and third years was 32% and 59%, respectively. These incidences are higher than in the general population, wherein the cumulative risk of subsequent SCC is 18% at 3 years. 17 Moreover, it has been demonstrated that the first NMSC's histological type predicts the subsequent type of neoplasm, as we observed in this study. 17, 18 This may occur due to immune tolerance to the first type of malignancy. Spain and Italy, where there is a predominance of BCCs over SCCs, at a ratio of 1.4:1 to 2.2:1. 10, 14, 20 The SCC:BCC ratio seems to decline at low latitudes, which may be explained by differences in sun exposure habits and genetic susceptibility to these cancers. 10, 16 It is speculated that the SCC:BCC ratio may be lower in Mediterranean countries due to the population's phenotypes (higher phototypes), which may be more protective against SCC than BCC in the first years after transplantation. Transplant Skin Cancer Collaborative. [22] [23] [24] Due to the lack of harmony in defining these characteristics, we analyzed risk features reviewed by Jennings that globally overlap with those considered primarily by the above-mentioned entities. 25 In locations such as the ear and non-glabrous lower lipthe most prevalent high-risk clinical locations in this populationthe estimated risk of lymph node metastasis is between 9-10% and 5-14%, respectively. 22, 25 Among the histological features associated with poor outcomes, tumor depths of over 4mm (30.23%) and the presence of desmoplasia/infiltration (23.26%) were the most commonly found risk factors. In a prospective study, depths greater than 4mm were linked to a metastasis rate of 9%, increasing to 16% when depths were over 6mm. 22 On the other hand, desmoplastic SCCs entail an increased risk of recurrence and nodal metastases (up to 6 times higher) and this rises with growing depths. 25 Only 7% of SCCs were larger than 2cm, which is currently the most important factor for T staging of AJCC. 24 When diameter weas neglected, we verified that 40% of SCCs presented at least two other high-risk features, which overlap with those defined by the AJCC. One of the current indications for immunosuppression revision is the presence of an SCC with at least two high-risk AJCC features (Chart 2). 26 Nevertheless, the occurrence of nodal metastases in 5% of cases -lower than the 8% previously reported in the KTR population -and the absence of deaths attributable to NMSC, may have resulted from early referral and treatment. years with those over 55 years. 27 Although males had a higher risk of NMSC in several studies, this was not reflected in our predominantly male population.
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viii) Role of immunosuppressive drugs
The impact of immunosuppressive drug use on the development of NMSC is well known. 2, 6 However, it has been difficult to establish a risk hierarchy of NMSC among the various drugs used in the KTR population.
Cyclosporine is the calcineurin inhibitor that most increases the risk of cancer in the general population -by 200 times for NMSC and 65 times for SCC. Tacrolimus seems to entail a lower increment in risk, especially when used in young recipients. The increase in risk with azathioprine is three times lower than with cyclosporine, while mycophenolate is the antimetabolite associated with the lowest risk. 28 In a prospective study by Wisgerhof, KTRs chronically treated with azathioprine presented a significantly higher risk of SCC than those treated with mycophenolate or cyclosporine. 17 Although it is less frequently used nowadays, azathioprine was the immunosuppressant of choice in the 80s and 90s. 29 In this study, azathioprine was the only drug, which, when evaluated alone or in combination with cyclosporine or prednisolone (regimen C), was associated with an increased risk of NMSC. Azathioprine has been recognized as a skin photosensitizing agent but it also provokes direct DNA damage through UVA radiation. 17 Hofbauer demonstrated that in KTRs, the photochemical damage previously inflicted on DNA is attenuated -but not completely reversed -in the long-term following discontinuation of azathioprine. 30 Sirolimus and everolimus are immunosuppressive drugs that work by inhibiting mTOR, which blocks the cellular response to IL-2 and does not allow for T-and B-lymphocyte activation. 19 We did not identify any protective effect on NMSC development in KTRs initially treated with sirolimus. In a recent meta-analysis, however, sirolimus was associated with a reduced risk of malignancy, including NMSC, in KTRs. The benefit was most pronounced in patients who converted from an established immunosuppressive regimen to sirolimus. Nevertheless, its use was linked to a significantly higher risk of death in both conversion and de novo trial subgroups. 
CONCLUSION
The overall incidence of NMSC found in this population, as well as the estimated cumulative incidence of the first and subsequent malignancies, are a cause for concern. Furthermore, the significant proportion of small-sized but high-risk invasive SCCs is also worrying. All physicians who follow up on these patients should be aware of risk factors for these neoplasms, especially for the oncogenic potential of different immunosuppressive drugs. Only strong articulation between dermatology departments and kidney transplant units can ensure early detection, treatment and secondary prevention of these cancers.q
